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Abstract
Background: Obesity-related cellular, metabolic, and molecular alterations have been shown to increase cancer risk and
tumor progression and are associated with poorer therapeutic outcome in cancer patients. However, the impact of
obesity and weight-control interventions on the therapeutic response in melanoma is poorly understood.
Methods: High fat diet (HFD)-induced obese mouse model was used in this study to evaluate the outcome of
dacarbazine (DTIC) therapy in melanoma. We employed LC-MS/MS to determine the quantity of the drug in tumor, and
in various tissues. Unique in vitro approach was used to complement in vivo findings by culturing melanoma cells in
either conditioned medium (CM) obtained from differentiated adipocytes or in serum collected from experimental mice.
Results: We report that diet-induced obesity impairs the outcome of DTIC therapy and reduces overall survival in
tumor-bearing mice. We provide evidence that obesity restricts the accessibility of DTIC to tumor tissue. Critically, upon
curtailing adiposity, accumulation and efficacy of DTIC is significantly improved. Moreover, using appropriate in vitro
approaches, we show that melanoma cells exhibit a drug-resistant phenotype when cultured in serum collected from
diet-induced obese mice or in CM collected from 3T3-L1 adipocytes. The impaired therapeutic response to DTIC in obese
state is mediated by fatty acid synthase (FASN), caveolin-1 (Cav-1), and P-glycoprotein (P-gp). The response to DTIC and
overall survival were improved upon employing weight control interventions in the tumor-bearing HFD-fed (obese) mice.
Conclusions: This study indicates that obesity not only supports rapid melanoma progression but also impairs the
outcome of chemotherapy, which can be improved upon employing weight control interventions. From clinically relevant
point of view, our study exemplifies the importance of lifestyle interventions in the treatment of obesity-promoted cancers.
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Background
Obesity, owing to excess adiposity, is associated with in-
creased risk of many cancer types [1–3]. With the unprece-
dented surge in global epidemic of obesity and overweight
population, incidences of obesity-associated health compli-
cations are also likely to increase [4, 5]. Adiposity-related
cellular, metabolic, and molecular alterations are known to
promote cancer risk and rapid tumor progression [3–7]
and adversely affect the response to cancer therapy [8].
However, the positive aspects of obesity management and
weight control interventions on the outcome of chemo-
therapy are not well understood.
Adipose tissue, an endocrine organ, is considered as one
of the critical factors involved in tumor progression, angio-
genesis, invasion, and metastasis [9–13]. Adipose tissue
expansion under persistent nutritional load alters serum
profile of adipokines, cytokines, and lipids [7, 10]. These
changes eventually create a state of chronic low-grade
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inflammation [14–16], which supports cancer cell survival
and proliferation [17, 18]. Adiposity in overweight and
obese people leads to dysregulation of adipocyte functions
and associated pathogenesis. Poor survival of cancer pa-
tients due to adiposity is an emerging, yet under explored,
issue of clinical significance. Meta-analysis of observational
studies has established a strong relationship between devel-
opment and progression of cancers including melanoma,
with obesity [1–3]. Melanoma, a life-threatening malig-
nancy which arises in the vicinity of subcutaneous adipose
tissue, accounts for the majority of skin cancer-associated
mortalities [19]. Obesity affects diagnosis and treatment
because of its interference with medical imaging, lowering
of tumor markers expression, alteration in the pharmaco-
kinetics of chemotherapeutic drugs, compromised immune
surveillance, improper precision of radiotherapy, and in-
creased risk of surgical complications and recovery time
[20–22]. In addition, tumor type and degree of adiposity
add up to the complexity of therapy and further restrict the
choices of chemotherapeutic drugs under obesity [20].
Contribution of adipocytes to chemoresistance of melan-
oma involves multiple signaling pathways and, hence, is
difficult to target them all [23].
Dacarbazine (DTIC) is the only US FDA-approved cyto-
toxic drug available for the treatment of metastatic melan-
oma with overall response rate of mere 20–25% [24].
Owing to its proximity to adipose tissue, under obesity,
melanoma assumes aggravated lethality with accompanying
drug resistance, which makes this association intriguing.
However, administration of DTIC at doses based on weight
or body size is a complicated medical issue which may have
adverse effects [25]. In contrast, any discretion to decrease
chemotherapy dose as in normal practice may lead to
exposure of cancer cells to a non-effective dosage of the
drug that potentially contributes to drug resistance. There-
fore, implications of strategy to control the proliferation
and invasiveness of cancer in the background of obesity by
containing adiposity need to be tested in a preclinical setup
before being explored clinically.
Previously, we reported that while diet-induced obesity
promotes melanoma growth [26], pharmacological and
dietary interventions targeting obesity reverse it to a great
extent [27]. Clinically, it has been proposed that a combin-
ation of changes in lifestyle together with pharmacological
approaches could be a more effective strategy for the man-
agement of obesity-promoted cancers [28–30]. In addition,
unlike their relatively lean counterparts, the obese cancer
patients require specific dosing for a curative response to
treatment and overall survival [25]. On these lines, we hy-
pothesized that weight control interventions in conjunction
with cancer chemotherapy could have a significant positive
impact on the management of obesity-promoted cancers.
By implicating pharmacological and dietary interventions
to contain adiposity, we have explored the therapeutic
outcome of DTIC in melanoma using appropriate in vitro
and in vivo models.
Methods
Experimental animals and diets
C57BL/6J mice were procured from Experimental Animal
Facility (EAF) at National Centre for Cell Science (NCCS),
Pune, India. High fat diet (24% fat) was purchased from
Provimi Animal Nutrition Pvt. Ltd., Bangalore, India, and
normal diet (5% fat) was obtained from Amrut Laboratory,
Pune, India. The compositions of diets are provided in sup-
plementary data (Additional file 1: Table S1). Diet-induced
obesity was developed in the mice by feeding them with
high fat diet as described previously [26, 27]. Male C57BL/6J
mice (6–8 weeks old) were divided into normal diet (ND)
and high fat diet (HFD) group. ND group was fed with nor-
mal diet while HFD group was fed with high fat diet supple-
mented with ground nut and dried coconut for 6 months.
Body weight and serum chemistry profile were measured
monthly to verify obesity-associated changes. Water and
food were provided ad libitum to all the mice. All animal
experiments were carried out as per the requirement and
guidelines of the Committee for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA), Govern-
ment of India, and after obtaining permission of the Institu-
tional Animal Ethics Committee (IAEC).
Cells and culture conditions
Murine melanoma cells B16F10 and B16F1 and murine
pre-adipocyte cells 3T3-L1 were procured from American
Type Culture Collection (ATCC, Manassas, VA, USA) and
maintained at our in-house cell repository at National
Centre for Cell Science, Pune, India. Cells were routinely
cultured in Dulbecco’s Modified Eagles Medium (DMEM)
supplemented with 10% heat inactivated fetal bovine serum
(Hyclone, UT, USA or Gibco, NY, USA), penicillin (100 U/
ml), and streptomycin (100 μg/ml) (Invitrogen Life Tech-
nologies, CA, USA) and maintained at 37 °C in a 5% CO2
humidified incubator (Thermo Fisher Scientific, OH, USA).
Serum biochemical analysis
Blood glucose levels and serum lipids were estimated as
described previously [26, 27]. Insulin, leptin, and adiponec-
tin levels in the serum were estimated by mouse-specific re-
spective ELISA kits as described [23]. Resistin, IL-6, and
TNF-α levels in the serum were detected by indirect ELISA
as described previously [27].
Orlistat treatment and/or diet shifting in HFD mice, tumor
challenge, DTIC administration, and follow-up
To study the impact of diet-induced obesity on the outcome
of DTIC therapy in melanoma, we treated B16F10 melan-
oma isografted obese mice with DTIC purchased from
Sigma, USA (80 mg/kg intraperitoneally for five consecutive
Malvi et al. Cancer & Metabolism  (2016) 4:21 Page 2 of 16
days as described previously) [31]. In addition, to look into
the impact of weight loss interventions on the outcome of
DTIC therapy in obese mice, mice were administered with
orlistat (an antiobesity drug known to inhibit gastrointes-
tinal lipases) and/or shifted from high fat to normal diet
followed by DTIC treatment. The detailed experimental
plan is illustrated in Fig. 1a. Briefly, obese mice were admin-
istered orally with orlistat (10 mg/kg on every alternate day)
purchased from Enzo Life Sciences, NY, USA, and/or
shifted from high fat diet to normal diet. HFD C57BL/6J
mice treated with vehicle or orlistat were termed as HFD-
HFD Ctrl and HFD-HFD Orli (N = 11 per each group),
respectively, whereas HFD C57BL/6J mice shifted to normal
diet and treated with vehicle or orlistat were grouped as
HFD-ND Ctrl and HFD-ND Orli (N = 11 per each group),
respectively. After 15 days, these mice were injected
subcutaneously (s.c.) with B16F10 cells (2 × 105) in 100 μl of
PBS and monitored daily for the presence of palpable tu-
mors and dimensions were recorded on alternate days.
When tumor size became approximately 40–50 mm3, all
groups of mice were treated with vehicle (acidified water)
or DTIC as mentioned above. Tumor volume was calcu-
lated using the formula 0.52 × length ×width2 and was
followed up throughout the study. At the end of the experi-
ment, mice were sacrificed by CO2 euthanasia. Excised
tumors’ volume and weight were recorded, and the samples
were immediately preserved at −80 °C until further use. To
observe their survival rates, five mice from each group were
followed up for an additional 60 days.
Orlistat treatment in ND mice, tumor challenge, DTIC
administration, and follow-up
For investigating whether oral delivery of orlistat influ-
ences DTIC treatment in melanoma-bearing ND C57BL/
6J mice, these mice were divided in to two major groups
(N = 11 per each group): ND mice treated with vehicle or
orlistat 15 days prior to injecting melanoma cells were
termed as (i) ND Ctrl and (ii) ND Orli, respectively. Mel-
anoma cells were injected and orlistat treatment was con-
tinued. Following tumor formation, all groups of mice
were treated with vehicle (acidified water) or DTIC, and
tumor volume was followed up in these mice throughout
the study as mentioned above. The detailed experimental
plan has been illustrated in Fig. 1a (ii). At the end of the
experiment, mice were sacrificed, tumors were excised,
and the samples were immediately preserved at −80 °C
until further use. Five mice from each group were
followed up for survival studies as mentioned above.
Immunoblotting
Melanoma tumor samples or cells were washed three to
five times with ice-cold PBS and lysed in ice-cold RIPA lysis
buffer as described previously [27]. Briefly, the samples
were centrifuged at 12000 RPM for 40 min and clear
supernatants were stored at −80 °C. Protein concentrations
were determined by Coomassie Plus Protein Assay Reagent
(Thermo Scientific, IL, USA). Equal amounts of protein
samples (50–100 μg) were resolved on 8–10% SDS-
polyacrylamide gel and then transferred onto PVDF mem-
brane (Millipore, MA, USA). The membranes were blocked
and further probed with antibodies against caveolin-1
(Cav-1) (1:1000), fatty acid synthase (FASN) (1:1000), pAkt
(Ser-473) (1:1000), total Akt (1:1000), PCNA (1:1000), cyc-
lin D1 (1:1000), β-tubulin (1:1000) (Santa Cruz Biotechnol-
ogy, CA, USA), and P-glycoprotein (P-gp) (1:1000) (Abcam,
MA, USA). After washing, the membranes were incubated
with HRP-conjugated secondary antibodies (1:2000) and
blots were developed using luminescence detection re-
agents (Santa Cruz Biotechnology, CA, USA).
LC-MS/MS analysis and quantitation of DTIC in tissue extracts
LC-MS/MS analysis was carried out on an Agilent 1290
Infinity ultra-high performance liquid chromatography
(UHPLC) system coupled to an Agilent 6540 UHD Accur-
ate Mass Q-TOF mass spectrometer equipped with a Dual
AJS electrospray ionization (ESI) source. The samples
were introduced to the mass spectrometer through a
reversed-phase column (Agilent ZORBAX SB-C18, 2.1 ×
30 mm, 3.5 μm). The mobile phase containing water and
acetonitrile with 0.1% formic acid was infused at a flow
rate of 0.4 ml min−1. The MS scan range was set between
100 and 1000 m/z, with the dry gas flow and dry gas
temperature maintained at 6 L min−1 and 320 °C, respect-
ively. Introduction of reference molecules with m/z,
121.05087, 149.02332, 322.04812, and 922.00979 ensured
consistency in mass accuracy over a wide mass range. All
the mass spectrometric data were acquired in positive
ionization mode using Agilent MassHunter data acquisition
software, version B.05.01. MassHunter Quantitative analysis
software, version B.07.00 was used for the generation of cali-
bration curves and subsequent quantitation of DTIC in the
samples. Calibration curves were created using linear fitting,
1/x weighting and including the origin. Calibration stan-
dards (0.5–800 ng) were prepared using standard DTIC. All
the samples including the standard DTIC preparations were
spiked with leucine enkephalin (10 ng) as internal standard.
Extracted ion chromatograms of DTIC (m/z, 183.0989) and
leucine enkephalin (m/z, 556.2766) were applied for quanti-
tation. The quantitation capability of this method is evalu-
ated by using samples with known concentrations.
Culture of melanoma cells in serum and conditioned medium
Approximately 1.5 × 102 B16F10 cells were plated in 24-
well plates and allowed to adhere. After 24 h, DMEM
containing 5% serum collected from experimental
C57BL/6J mice (as illustrated in Fig. 1) was added and
cells were cultured chronically for 10 days. Medium was
changed on every 2–3 days. Thereafter, cells were fixed with
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paraformaldehyde and stained with crystal violet, and images
were taken using digital camera (Olympus, Tokyo, Japan).
3T3-L1 cells were plated in 35-mm dishes and differenti-
ated as described [32], along with vehicle or orlistat treat-
ment (50 μM). The medium was changed every alternate
day and fresh medium containing orlistat or cerulenin (an
inhibitor of FASN) was added to the cells. After 11 days,
medium was removed and cells were washed twice with
DMEM. Fresh DMEM was added and cells were incubated
for further 18 h. For culturing the melanoma cells, condi-
tioned medium (CM) was mixed with fresh DMEM in 1:1
ratio. Approximately 3 × 102 B16F10 cells were plated in
12-well plates and cultured chronically for 10 days in this
CM. Thereafter, crystal violet staining was performed to
verify long-term survival, and the plates were photographed.
MTT assay
Melanoma cells were plated at a density of 6 × 103 cells/
well in 96-well plates and allowed to adhere. After 24 h,
cells were treated with vehicle (PBS or ethanol), inhibi-
tors, or drugs as per the experimental requirements.
After treatment duration, medium was removed and
50 μl of MTT (methylthiazole tetrazolium, 1 mg/ml in
DMEM without phenol red) (Sigma-Aldrich, MO, USA)
was added in each well and further incubated for 4 h at
37 °C. Formazan crystals were solubilized in 100 μl of
isopropanol, and absorbance was measured at 570 nm.
Long-term survival assay
Melanoma cells were plated at a density of 3 × 102 cells/well
in 12-well plates. Next day, these cells were treated with ve-
hicle or orlistat as per the experimental requirements. After
48 h, medium was removed and fresh medium was added.
Cells were allowed to grow for 10 days with medium
change on every 2–3 days. Thereafter, cells were fixed with
3% paraformaldehyde for 10 min and stained with 0.05%
crystal violet for 2 h at room temperature. Images were
taken using digital camera (Olympus, Tokyo, Japan).
Rhodamine-123 efflux assay
To measure the efflux of Rhodamine-123 (Rh-123), which
is reflective of transport activity for P-gp, melanoma cells
were seeded at a density of 1 × 103 cells/well in 35-
mm culture dishes and allowed to adhere for 24 h.
Thereafter, these cells were chronically cultured in
DMEM containing serum collected from experimental
mice or in CM form 3T3-L1 cells for 10 days with
medium change on every 2–3 days. Cells were
washed thrice with PBS and incubated for 30 min at
37 °C in PBS containing 2 μM Rh-123. Further, Rh-
123 efflux was measured using Flow cytometer. Fluor-
escence intensity of Rh-123 was acquired using FACS
Calibur, and the data were analyzed using CellQuest
Pro software (BD Biosciences, CA, USA).
Immunofluorescence confocal staining
Melanoma cells were plated in multi-well chambered
slides (MP Biomedicals, OH, USA) and allowed to
grow for 24 h. Next day, medium was changed to
DMEM supplemented with serum from ND or HFD
mice or in CM collected from 3T3-L1 cells for
10 days. Subsequently, these cells were washed with
PBS, and immunofluorescence staining was performed
as described previously [26].
Inhibitor-based in vitro studies
Melanoma cells were seeded at an appropriate density in
culture dishes or well plates and allowed to adhere. After
24 h, cells were grown in DMEM containing serum
collected from experimental mice or in CM collected from
3T3-L1 cells in the presence of vehicle or pharmacological
inhibitors for 48 h. Thereafter, cells were processed for
MTT assay or long-term survival assay or Rhodamine-123
efflux analysis as mentioned above.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
7.0 (GraphPad Software Inc., CA, USA). All data are pre-
sented as the mean ± standard deviation (S.D.). For in vitro
experiments, bars represent variations within the wells of
the experiment. The experiments were repeated at least
three times. For in vivo experiments involving more than
two groups, one-way ANOVA was used, followed by the
Tukey multiple comparison test. In vitro or in vivo data
(See figure on previous page.)
Fig. 1 Diet-induced obesity impairs the outcome of DTIC therapy in melanoma which is improved upon employing weight control interventions. a Impact
of diet-induced obesity on the outcome of DTIC therapy in melanoma isografted HFD C57BL/6J mice (i). Effect of treatment of orlistat, at antiobesity dose
(10 mg/kg, oral), on the outcome of DTIC therapy in melanoma isografted ND C57BL/6J mice (ii). b ND male C57BL/6J mice were divided into two major
groups. One group was orally treated with orlistat (10 mg/kg), and the other group was treated with vehicle control on every alternate day for 8 weeks.
Both the groups of mice (N= 11 per each group) were injected with B16F10 cells (2 × 105 cells/mouse in 100 μl PBS). After tumor formation, vehicle or DTIC
treatment was given as per the experimental layout shown in Fig. 1. (i) Tumor volume, (ii) tumor weight, and (iii) survival of tumor-bearing mice (N= 5 mice
per group). c HFD male C57BL/6J mice were divided into two major groups. One group was continuously fed with HFD, whereas the other group was
shifted from HFD to ND. Mice from both the groups were orally treated with orlistat (10 mg/kg) or vehicle control on every alternate day for 8 weeks. All
the groups of mice (N= 11 per each group) were injected with B16F10 cells (2 × 105 cells/mouse in 100 μl PBS). After tumor formation, vehicle or DTIC
treatment was given as per the experimental layout shown in Fig. 1. (i) Tumor volume, (ii) tumor weight, and (iii) survival of tumor-bearing mice (N= 5 mice
per group). The results are given as means ± standard deviation; *p< 0.05, **p< 0.01, ***p< 0.001, and ****p< 0.0001 denote significant differences between
the groups; NS non-significant
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involving two experimental groups were analyzed using
two-tailed unpaired Student’s t test. The values of p < 0.05,
p < 0.01, p < 0.001, and p < 0.0001 were considered as statis-
tically significant (*), very significant (**), highly significant
difference (***), and very highly significant difference (****),
respectively, unless otherwise mentioned.
Results
Diet-induced obesity impairs the outcome of DTIC
therapy in melanoma
We have reported previously that diet-induced obesity and
weight loss interventions influence melanoma progression
[26, 27]. Among many, diet is one of the important factors
that influence chemotherapeutic response in patients.
Therefore, to investigate whether diet-induced obesity or
dietary interventions could dictate the outcome of chemo-
therapy in melanoma, we developed diet-induced obesity
by chronic feeding of C57BL/6J mice with high fat diet as
described previously [26, 27]. After developing diet-induced
obese phenotype, ectopic isografts were induced by inject-
ing B16F10 cells as shown in the experimental layout in
Fig. 1a (i). Upon the appearance of palpable tumors, DTIC
was administered in these mice and tumor volume and
obesity-associated parameters were regularly monitored.
Parallely, similar experiment was performed in normal diet-
fed (ND) mice (Fig. 1a (ii)). As expected, tumor progression
was significantly reduced in ND mice treated with DTIC as
compared to control (Fig. 1b (i), (ii)). Additionally, DTIC
treatment prolonged the survival of ND mice in compari-
son to the untreated tumor bearing mice (Fig. 1b (iii)).
Surprisingly, enhanced tumor growth in HFD mice treated
with DTIC in comparison to their untreated counter parts
at the same dosage was observed (Fig. 1b (i), (ii)). In
untreated HFD mice, overall survival was reduced when
compared to their respective ND counter parts. Moreover,
survival in HFD mice was reduced due to increased tumor
burden under DTIC treatment (Fig. 1c (iii)). Further, to
confirm whether DTIC treatment itself altered obesity-
associated parameters in ND and HFD mice, serum chem-
istry profiles were assessed. We found that DTIC per se did
not affect the levels of obesity-associated factors in ND and
HFD mice as compared to their respective untreated
controls (Table 1 and Additional file 2: Table S2). These
results indicate that diet-induced obesity impairs the out-
come of DTIC therapy in melanoma.
Weight control interventions improve the efficacy of DTIC
in obese mice
In order to look into whether controlling adiposity has any
influence on the tumor progression, HFD mice were sub-
jected to weight loss interventions. We used both pharma-
cological and diet control procedures as described in our
previous study [27]. Following oral administration of
orlistat (10 mg/kg on every alternate day) and/or shifting
obese mice from high fat to normal diet (HFD to ND), on
the 15th day, B16F10 melanoma cells were injected.
Subsequently, tumor progression and obesity-associated
parameters were regularly monitored till the termination of
the experiment (Fig. 1a (i)). Similar experiments were also
carried out in ND mice to further verify if orlistat, at an
antiobesity dose, affects the efficacy of DTIC (Fig. 1a (ii)).
Firstly, we monitored whether diet/weight control inter-
ventions alter obesity-associated parameters. Normalization
in the levels of obesity-associated factors was observed upon
orlistat treatment or by shifting experimental HFD mice to
normal diet (Table 1). Interestingly, in these mice, the levels
of obesity-associated factors were found to be close to the
levels in ND mice, particularly when orlistat administration
was combined with diet shifting (Table 1). However, obesity-
associated factors were unaffected in DTIC-treated group as
compared to respective untreated controls (Table 1).
Next, we checked if orlistat, at antiobesity dose, influenced
the outcome of DTIC therapy in ND mice. Consistent with
the results of our previously published study [24], tumor
volume and weight were found to be unaltered in ND mice
administered with antiobesity dose of orlistat, as compared to
control mice (Fig. 1b (i), (ii)). DTIC significantly decreased
tumor volume and weight in ND mice. However, no further
change in the tumor growth was observed in the mice receiv-
ing orlistat and DTIC as compared to DTIC alone. Similarly,
orlistat treatment did not influence overall survival of mice as
compared to mice receiving only vehicle (Fig. 1b (i–iii)). Also,
no significant change in the overall survival was observed in
mice receiving DTIC alone or mice receiving DTIC and
orlistat together (Fig. 1b (i–iii)). Thus, orlistat neither altered
the tumor-reducing effect of DTIC nor improved survival in
ND mice. Moreover, levels of obesity-associated factors were
also not altered (Additional file 1: Table S1), suggesting that
orlistat per se does not influence the response to DTIC in
ND mice. Interestingly, in tumor-bearing HFD mice, we ob-
served that weight control interventions by orlistat treatment
or diet shifting not only restricted tumor growth but also im-
proved the efficacy of DTIC, as is evident by reduction in
tumor volume and weight (Fig. 1c (i), (ii)), and survivability
increased by 40% (Fig. 1c (iii)). Furthermore, DTIC treatment
was much more effective in retarding tumor growth and in
improving overall survival when orlistat administration was
combined with dietary intervention (80% survival at day 60
in case of orlistat treatment and 100% upon combining diet
and orlistat) (Fig. 1c (i–iii)). Survivability of tumor-bearing
mice receiving orlistat and DTIC therapy or diet control
together with orlistat and DTIC was prolonged up to 90 and
100 days, respectively, in comparison with 60 days for HFD
mice receiving DTIC only. These observations were in
parallel with normalization in obesity-associated parameters
in HFD mice, suggesting that reducing adiposity by weight
loss interventions profoundly improves the efficacy of DTIC
and increases overall survival of tumor-bearing mice.
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Table 1 Evaluation of obesity-associated factors in HFD C57BL/6J mice
Parameters C57BL/6J HFD
HFD-HFD Ctrl HFD-HFD DTIC HFD-HFD Orli HFD-HFD Orli DTIC HFD-ND Ctrl HFD-ND DTIC HFD-ND Orli HFD-ND Orli DTIC








































































































































































Evaluation of obesity-associated factors in HFD C57BL/6J mice. Obesity-associated parameters in the experimental HFD mice recorded at the end of the experiment. HFD male C57BL/6J mice were divided into two
major groups. One group was continuously fed with HFD, whereas the other group was shifted from HFD to normal diet. Mice from both the groups were orally treated with orlistat (10 mg/kg) or vehicle control on
every alternate day for 8 weeks. All the groups of mice (N = 11 per each group) were injected with B16F10 cells (2 × 105 cells/mouse in 100 μl PBS). After tumor formation, vehicle or DTIC treatment was given as per
the experimental layout shown in Fig. 1. Their body weight was monitored weekly throughout the study, and serum was collected at the end of the experiment. Blood glucose, serum TG, serum cholesterol, serum-free












Elevated levels of tumor-promoting molecules and rapid
efflux of DTIC contribute to impaired response
To get mechanistic insights, we sought to explore the mo-
lecular events contributing to impaired response to DTIC,
in diet-induced obesity. To understand as to why DTIC
treatment leads to enhanced tumor growth in obese mice,
we checked the levels of molecules involved in tumor pro-
gression under obese state. Fatty acid synthase (FASN) is a
key molecule associated with increased proliferation, sur-
vival, and drug resistance in various cancer cells including
melanoma. We have earlier reported that increased level
of FASN and caveolin (Cav)-1 contributes to the enhanced
tumor growth in obese mice [26]. In the present study, we
found that FASN level was further increased and Cav-1
levels was also elevated in tumors of HFD mice treated
with DTIC (Fig. 2a). On the contrary, as anticipated,
FASN and Cav-1 level was much lower in ND mice
treated with DTIC (Fig. 2a). Additionally, to verify
whether enhancement in the tumor growth is because of
increase in proliferation of melanoma cells following
DTIC treatment in obese mice, we checked the level of
proliferative molecules. It was found that DTIC treatment
caused increase in protein levels of cyclin D1 and prolifer-
ating cell nuclear antigen (PCNA) in tumors from HFD
mice (Fig. 2a). In contrast, reduced levels of these proteins
were detected in tumors of ND mice treated with DTIC
(Fig. 2a). Changes in level of these molecules were associ-
ated with concomitant alteration in the phosphorylation
of Akt, an important kinase involved in cell growth, sur-
vival, proliferation, and other vital cellular functions [33].

























































ND Ctrl ND DTIC
1 1.3 0.6 0.7
1 1.1 0.6 0.7
1 1.2 0.4 0.3
1 0.9 0.5 0.4
1 0.9 0.6 0.6
1 1.2 0.4 0.3
HFD-HFD Ctrl HFD-HFD DTIC
2.5 3.3 6.2 5.8
1.2 2.0 2.4 2.6
2.5 2.4 3.0 3.8
1.1 1.6 3.0 2.9
1.2 1.4 2.7 4.3
1.2 1.3 1.7 2.1
Fig. 2 Molecular events associated with the impaired response to DTIC therapy in tumors of the experimental B16F10 isografted mice. a Western blot
analysis of lysates from tumors of experimental HFD or ND mice subjected to SDS-PAGE and probed for levels of FASN, P-gp, Cav-1, pAkt, PCNA, and
cyclin D1 in ND or HFD C57BL/6J mice treated with or without DTIC. b B16F10 or B16F1 cells were chronically grown in medium containing 5% serum
collected from ND or HFD C57BL/6J mice for 15 days. Thereafter, these cells were subjected to immunofluorescence confocal staining of the indicated
molecules (scale bar = 20 μm). c Quantitative determination of DTIC concentration in the tumor, plasma, liver, and adipose tissues excised from the
indicated group of mice. Level of DTIC was determined by mass spectrometric analysis. The results are given as means ± standard deviation; *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001 denote significant differences between the groups; NS non-significant
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Furthermore, we explored the molecular events those
might be involved in mediating impaired therapeutic out-
come of DTIC under obese background. We speculated
that, because of increased expression of P-glycoprotein (P-
gp), tumor cells are not able to retain sufficient quantity of
DTIC. This would cause hindrance in the accumulation of
an effective concentration of drug in cells. P-gp is a multi-
drug resistance protein associated with pumping out drugs
from the resistant cells [34]. Therefore, we checked the
level of P-gp in the tumors of HFD mice administered with
or without DTIC. Level of P-gp, which was found to be
elevated in tumors of HFD mice, was further increased in
tumors from DTIC-treated HFD mice. Under similar
setup, DTIC treatment in ND mice reduced the level of P-
gp (Fig. 2a). Immunofluorescence staining confirmed the
increased expression and localization of P-gp to plasma
membrane in B16F10 and B16F1 cells grown in HFD
serum as compared to cells cultured in ND serum of
C57BL/6J mice (Fig. 2b and Additional file 3: Figure S1,
respectively).
To confirm the presence of DTIC in vivo, we checked the
distribution of DTIC in tumors and other vital organs by
mass spectrometry. We observed significantly reduced level
(~6-fold less) of DTIC in tumors excised from HFD mice as
compared to the level in ND counterparts (Fig. 2c). DTIC
level in the plasma, liver, and adipose tissue from HFD mice
was higher as compared to ND mice (Fig. 2c). Concentration
of DTIC was found to be even lesser in tumors than in other
tissues excised from HFD mice (Fig. 2c). Interestingly, obes-
ity control interventions significantly improved accumulation
of DTIC in tumors from HFD mice with concomitant de-
crease in amount of DTIC in the plasma, liver, and adipose
tissue (Fig. 2c). Collectively, these results suggest that in-
creased levels of FASN, Cav-1, and P-gp in tumors are asso-
ciated with increased tumor growth and impairment in the
outcome of DTIC therapy in melanoma under obese state.
FASN, Cav-1, and P-gp are involved in impaired response
of melanoma to DTIC treatment under obesity
To corroborate in vivo findings in vitro, we cultured
B16F10 cells in serum collected from ND and HFD
C57BL/6J mice. These cells were treated with varying con-
centrations of DTIC. Similar to in vivo findings, we ob-
served that B16F10 cells cultured in the medium
containing HFD serum showed an impaired response to
DTIC (Fig. 3a) and inhibitory concentration (IC50) of
DTIC was significantly increased (~5-fold more) as com-
pared to B16F10 cells cultured in medium containing ND
serum (Fig. 3a). The IC50 of DTIC (1415 μM) for cells cul-
tured in medium containing ND serum was used for all in
vitro experiments performed on cells cultured in serum
collected from the experimental mice. Further, to verify
the functional status of P-gp in obese state, we performed
rhodamine 123 (Rh-123) efflux assays. In B16F10 and
B16F1 cells cultured chronically in HFD serum, Rh-123
efflux was higher as compared to those cultured in ND
serum (Fig. 3b and Additional file 4: Figure S2, respect-
ively). Moreover, Rh-123 efflux was reduced in cells cul-
tured in medium containing serum from orlistat-treated
and/or diet-shifted mice (Fig. 3b and Additional file 4: Fig-
ure S2), which correlates with normalized serum levels of
obesity-associated factors. The increase in Rh-123 efflux
in the cells grown in medium supplemented with HFD
serum was reversed upon treatment with verapamil, an in-
hibitor of P-gp, (Fig. 3b and Additional file 4: Figure S2)
confirming the involvement P-gp in the impaired response
to DTIC in melanoma under obese state.
Consistent with above stated findings, impairment in
the response of B16F10 and B16F1 cells cultured in HFD
serum condition to DTIC, in a long-term survival assay
was very clearly visible. In B16F10 and B16F1 cells cul-
tured in medium containing serum from orlistat-treated
or diet-shifted obese mice, cell survival was reduced by ap-
proximately 70 and 75% respectively, upon DTIC treat-
ment (Fig. 3c, d and Additional file 5: Figure S3). Survival
was drastically reduced in the cells cultured in medium
containing serum from orlistat-treated or diet-shifted
obese mice upon treatment with DTIC, which was com-
parable with the response to DTIC, in ND serum cultured
cells (Fig. 3c, d and Additional file 5: Figure S3).
Next, to ascertain the involvement of FASN, Cav-1, and
P-gp in the impaired response to DTIC in B16F10 cells
cultured in the presence of serum from HFD and ND
mice, long-term clonogenic survival assay was performed
in the presence or absence of inhibitors of these molecules.
We observed that inhibition of these molecules individu-
ally increased the cytotoxicity of DTIC in cells cultured in
medium containing HFD serum. Moreover, sensitivity of
B16F10 and B16F1 cells to DTIC was greatly increased
(approximately 80%) when all the three molecules were
simultaneously inhibited (Fig. 3c, d and Additional file 5:
Figure S3). Therefore, it is likely that FASN, Cav-1, and P-
gp are cumulatively responsible for impairment in the out-
come of chemotherapy in melanoma.
Adipocyte-secretory factors impair the response of
melanoma to DTIC
Above stated observations suggest that controlling obesity
was associated with improved response to DTIC in obese
mice, which in turn, implies an inter-relationship between
normalization in the obesity-associated factors and cellular
sensitivity. Melanoma cells grown in the serum collected
from obese mice showed poor response to DTIC while re-
verse was obtained for cells grown in the serum collected
from either orlistat treated or diet shifted. Therefore, we
speculated that poor response to the DTIC therapy in
melanoma under obesity might be influenced by obesity-
associated secretory factors. Thus, we explored the role of
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adipocyte-secreted factors towards the response of melan-
oma cells to DTIC. To consolidate our observations, we uti-
lized 3T3-L1 cells, which are considered as in vitro model
for adipocyte-secreted factors. For this, 3T3-L1 cells were in-
duced to differentiate in the presence or absence of orlistat
(an inhibitor of adipocyte differentiation) for 11 days, and
the conditioned medium (CM) from these cells was col-
lected. B16F10 cells were cultured in CM and treated with
varying concentrations of DTIC. As expected, we noticed
that B16F10 cells cultured in CM from differentiated adipo-
cytes showed impairment in the response to DTIC (Fig. 4a).
Cells grown in the CM from differentiated adipocytes
required much higher concentration (~5-fold more) of drug
to achieve 50% cell killing as compared to those grown in
the CM of undifferentiated/preadipocytes (Fig. 4a),
suggesting that adipocyte secretary factors indeed contribute
towards poor response of melanoma cells to DTIC under
obese state. IC50 value of DTIC (649 μM) for cells cultured
in CM from undifferentiated preadipocytes was used for all
the experiments involving melanoma cell culture.
Further, to confirm the molecular events involved in im-
paired response to DTIC, B16F10 and B16F1 cells were
chronically grown in CM collected from undifferentiated
(PA) and differentiated (ID) 3T3-L1 cells for 10 days. Using
immunofluorescence staining, we observed that the level of
FASN, Cav-1, and P-gp was increased in the cells cultured
in CM from differentiated adipocytes in comparison to
those cultured in CM from undifferentiated preadipocytes
(Fig. 4b and Additional file 6: Figure S4). This suggests that





Fig. 3 Effect of obesity-associated serum factors on survival of B16F10 cells upon DTIC treatment. a Calculation of IC50 value of DTIC in DMEM containing
ND or HFD serum. B16F10 cells were chronically grown in medium containing 5% serum collected from ND or HFD C57BL/6J mice for 10 days. These cells
were then subjected to DTIC treatment at the indicated concentrations for 48 h. Thereafter, MTT assay was performed. b Rh-123 efflux assay in B16F10 cells
cultured in the medium containing serum from experimental mice. Data were acquired on FACS Calibur and analyzed using BD CellQuest Pro software. c,
d Long-term survival assay in B16F10 cells cultured in the medium containing serum from experimental mice in the presence of inhibitors of FASN, Cav-1,
and P-gp, either alone or together with DTIC (c). Data were quantitated using ImageJ software (d). The data are representative of experiments performed
three times; Ceru or C = cerulenin; MCD or M=methyl β-cyclodextrin; Vera or V = verapamil. The results are given as means ± standard deviation; *p< 0.05,
**p< 0.01, ***p< 0.001, and ****p< 0.0001 denote significant differences between the groups; NS non-significant
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modulating FASN, Cav-1, and P-gp levels which, in turn,
influence the outcome of DTIC therapy in melanoma cells.
To mechanistically analyze the involvement of adipocyte-
secreted factors in modulating P-gp expression and its func-
tionality, Rh-123 efflux assay was performed. We observed
that B16F10 cells grown chronically in the CM from differ-
entiated adipocytes exhibited increased efflux of Rh-123
dye. In contrast, enhanced retention of Rh-123 was detected
in B16F10 and B16F1 cells grown in CM from undifferenti-






Fig. 4 Adipocyte-secreted factors impair the response of melanoma cells to DTIC. a Calculation of IC50 value of DTIC in CM from 3T3-L1 cells. B16F10 cells
were chronically grown in conditioned medium (CM) collected from 3T3-L1 cells for 10 days. These cells were then subjected to DTIC treatment at the
indicated concentrations for 48 h. Thereafter, MTT assay was performed. b Immunofluorescence confocal staining of P-gp, Cav-1, and FASN in B16F10 cells
cultured in CM collected from 3T3-L1 cells (scale bar= 20 μm). c Rh-123 efflux assay in B16F10 cells cultured in the CM from 3T3-L1 cells. d, e Long-term
survival assay in B16F10 cells cultured in the CM from adipocytes in the presence of inhibitors of FASN, Cav-1, and P-gp, either alone or together with
DTIC (d). Data were quantitated using ImageJ software (e). The data are representative of experiments performed three times; PA = preadipocytes; ID =
differentiated adipocytes; Orli = orlistat; Ceru or C = cerulenin; MCD or M=methyl β-cyclodextrin; Vera or V = verapamil. The results are given as means ±
standard deviation; *p< 0.05, **p< 0.01, ***p< 0.001, and *****p< 0.0001 denote significant differences between the groups; NS non-significant
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Thus, reduced uptake in B16F10 and B16F1 cells is likely a
consequence of overexpression of P-gp, which is responsible
for the efflux of drugs from the cells. The involvement of P-
gp was further confirmed by treating B16F10 and B16F1
cells cultured in CM from differentiated adipocytes with
verapamil, which increased Rh-123 retention in this setting
(Fig. 4c and Additional file 7: Figure S5). These findings
suggest that P-gp plays a crucial role in the impairment of
chemotherapeutic response under obesity which is primarily
mediated by adipocyte-secreted factors.
Differentiation of 3T3-L1 adipocytes is inhibited by orli-
stat, which leads to reduction in the levels of adipocyte-
secreted factors [24]. We sought to determine whether the
diminished level of adipocyte-secreted factors (under inhib-
ition of adipocyte differentiation by orlistat) has any impli-
cations in the response of B16F10 cells to DTIC. We also
noticed that the rate of Rh-123 retention was increased in
B16F10 cells cultured in CM from orlistat-treated differen-
tiating adipocytes (Fig. 4c and Additional file 7: Figure S5).
Next, long-term colony formation assay was performed to
verify whether CM obtained from either preadipocytes or
differentiated adipocytes could influence the survival of
melanoma cells in presence of the drug. DTIC treatment
did not remarkably affect the survival of B16F10 and B16F1
cells grown in CM collected from differentiated ID adipo-
cytes (Fig. 4d, e and Additional file 8: Figure S6). The
survival of B16F10 and B16F1 cells cultured in CM from
orlistat-treated differentiating adipocytes was reduced
significantly to approximately 30% upon DTIC treatment
(Fig. 4d, e and Additional file 8: Figure S6), suggesting that
reduction in the level of secretory adipokines correlates
with improved response to DTIC. Mechanistically, the
sensitivity of B16F10 and B16F1 cells grown in CM
collected from differentiated adipocytes to DTIC was in-
creased upon inhibiting FASN, Cav-1, and P-gp individually
(Fig. 4d, e and Additional file 8: Figure S6). Sensitivity to
DTIC improved dramatically (approximately 80%) upon
simultaneous treatment with all the three inhibitors (Fig. 4d,
e and Additional file 8: Figure S6).
Discussion
In the present study, we report that diet-induced obesity is
associated with impaired response of melanoma to DTIC.
Importantly, weight loss interventions can significantly
improve the therapeutic efficacy of DTIC. As adiposity
influences tumor progression, a combination treatment of
obesity together with anticancer therapy is likely to
improve survival [28]. Herein, we targeted adiposity and
nutrient signaling together, to enhance the therapeutic ef-
ficacy of DTIC. This study provides insights on reduction
in obesity by orlistat and diet restriction improves sensitiv-
ity of melanoma to DTIC, thereby prolonging survival.
However, cachexia (a multifactorial wasting syndrome,
characterized by the loss of adipose tissue and muscle)
and severe weight loss are common in the advanced
melanoma, and therefore, the adverse effects of obesity
may be more important at relatively early stages of the
disease. Use of orlistat as an antiobesity agent serves
multiple purpose: (i) an inhibitor of lipase and hence re-
duction in absorption of fat by intestine [35], (ii) reported
to possess anticancer property [36], and (iii) as an inhibi-
tor of differentiation of preadipocytes to adipocytes [27].
Our study provides a preclinical evidence that the out-
come of DTIC treatment is impaired in obese mice. Sur-
prisingly, DTIC treatment instead of restricting growth
actually promotes rapid tumor growth in obese mice
causing decreased overall survival of tumor-bearing
obese mice, as compared to untreated counterparts. This
observation raises a serious question as to why DTIC
treatment paradoxically promotes melanoma growth,
and decreases overall survival under obese state. Earlier,
it has been reported that chronic exposure of cisplatin
to lung cancer cells enhances damage repair and tumor
progression [37]. Moreover, Lev et al. have also shown
that DTIC promotes rapid melanoma growth and metas-
tasis by increasing the levels of IL8/VEGF [38, 39].
Our results show that levels of P-gp and other molecules
involved in drug resistance such as FASN and Cav-1 are el-
evated in tumor excised from obese mice treated or un-
treated with DTIC as compared to mice kept on ND.
Increase in the level of FASN and Cav-1 has been reported
to be associated with development of resistance to cancer
therapy [40–42]. Recently, we have shown that Akt medi-
ates increased melanoma progression under obese state
[27] and is also involved in regulating drug-resistant pheno-
type in several cancers [43]. Plasma membrane-associated
molecule P-gp, which belongs to multidrug resistance
(MDR) family of proteins, is involved in the efflux of drugs
from cancer cells [44, 45]. Importantly, there is a molecular
link between FASN, Cav-1, and P-gp signaling pathways
which is regulated by adipokine-driven Akt activation
under obese state. We have previously reported that FASN
and Cav-1 interact with each other and are regulated by
adipokines [23]. FASN modulates Cav-1-dependent signal-
ing pathways and controls proliferation of cancer cells [42].
Since Cav-1 is a membrane protein and is reported to be
associated with drug-resistant phenotype, it is quite likely
that it might directly or indirectly influence the activity of
P-gp. Owing to the enhanced activity of P-gp, tumor cells
accumulate very less amount of DTIC under obese state as
compared to its lean counterparts. This leads to propor-
tional increase in the level of DTIC in plasma and accumu-
lation in other vital organs (Additional file 9: Figure S7).
Excess accumulation of DTIC in normal organs under
obese state may contribute to toxicity and thus also affect
overall survival.
Our in vivo and in vitro data suggest that obesity-
associated factors themselves promote drug-resistant
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phenotype in cancer cells. Moreover, it has been reported
that drug-resistant cells are highly aggressive and grow rap-
idly as compared to untreated counterparts [37–40]. There-
fore, enhanced tumor growth owing to the DTIC treatment
under obese state can be explained based on following pos-
sibilities. First, due to the accumulation of low quantity of
drug in cells under obese state, cancer cells can develop
drug-resistant phenotype which is typically more aggressive
than untreated cells. Secondly, it has been reported that can-
cer cells exhibit enhanced damage repair mechanism against
DNA intercalating drugs [37]. Owing to the robust DNA re-
pair mechanism, melanoma cells can also escape from the
cytotoxic effect of drugs. DTIC induces cytotoxicity in can-
cer cells by inducing DNA damage, which actually depends
on the quantity of drug present in the nucleus. Put together,
insufficient quantity of DTIC present in the cancer cells
under obese condition coupled with the ability to rapidly
clear DTIC-DNA adduct might promote the development
of aggressive phenotype. Moreover, chromosomal abnormal-
ity due to abnormal repair mechanisms could also aggravate
the melanoma growth. Yet another mechanism that could
contribute to the rapid growth is enhanced secretion of
IL8/VEGF by cancer cells in response to drugs [38, 39].
Furthermore, activation of Akt signaling pathway and
increased level of FASN and Cav-1 contribute to drug-
resistant phenotype under obese state [26, 27, 42].
Therefore, it is likely that adipokine-driven activation
of signaling pathways and underexposure of drugs lead
to development of highly aggressive melanoma pheno-
type in obese mice.
Epidemiological studies have shown that weight loss
alleviates obesity-associated complications and produces
disproportionate benefit to health [46]. Data from observa-
tional and calorie-restriction studies in animal models sup-
port a beneficial role for weight loss interventions in
counteracting neoplasia-promoting role of obesity [22, 28].
Interestingly, by employing the strategy to control adiposity,
we show that orlistat treatment or shifting from HFD to
ND improves DTIC efficacy and increases overall survival of
mice. And further, combining these two strategies together
leads to improvement in the therapeutic outcome of DTIC
and prolong survival of obese mice. Moreover, we report
that when obesity was controlled by using pharmacological
or dietary interventions, the levels of FASN, Cav-1, and P-
gp were reduced which correlates with improvement in the
effectiveness of DTIC on ectopic tumors in mice. Interest-
ingly, weight control intervention profoundly increases the
accumulation of DTIC in tumor and subsequently reduces
its level in plasma and other tissues. These findings suggest
that controlling adiposity/body weight is beneficial towards
the outcome of chemotherapy and may contribute towards
reduction in generalized toxicity to organs. Additionally,
this may also be helpful in preventing the development of
drug-resistant phenotype in cancers.
Studies from in vitro and in vivo results conclude that
stored fat, and adipokines, the adipocyte-derived factors or
hormones, aid in the progression of melanoma by up-
regulating and driving multiple etiological pathways and
regulating signaling cascades [47–49]. Adipokines can spe-
cifically trigger several distinct transcriptional programs,
those that promote tumorigenesis, cell survival and prolifer-
ation, and angiogenesis and invasiveness [50–52]. Altered
secretion profile of leptin, and adiponectin, and other in-
flammatory adipokines such as IL-6 and TNF-α, by interact-
ing with signaling network, accelerate neoplasia [13]. These
factors by enhancing P-gp may promote drug efflux, causing
accumulation of drug in plasma and induce toxicity to vital
organs. In addition, the nutrients and net available energy
are also crucial factors that decide the fate of both normal
and malignant cells. However, assessing net energy intake
and expenditure is difficult to evaluate in humans. Nutrient
signaling is an integral part of metabolic regulatory network
and links nutrient availability with cell growth and prolifera-
tion. Therefore, it is rational to target adipose tissue with
antiobesity drug and energy restriction simultaneously.
Using unique strategy by growing melanoma cells in ei-
ther serum collected from obese mice treated or untreated
with DTIC or orlistat, as well as in conditioned medium
collected from adipocytes, we show that adipocyte secretory
factors actually modulate the therapeutic response of melan-
oma cells to DTIC. Adipocytes are also known to protect
leukemia and breast cancer cells from chemotherapy and
radiotherapy, respectively [53, 54]. On the similar line, our
study demonstrates that melanoma cells grown in the
presence of serum collected from obese mice as well as in
the CM collected from differentiated adipocytes cause an in-
crease in IC50 value of DTIC, suggesting that adipocyte-
secreted factors adversely affect the outcome of chemother-
apy. Melanoma cells grown under these conditions develop
chemo-resistant phenotype, characterized by increased ex-
pression of FASN, Cav-1, and P-gp. Inhibition of these mol-
ecules reverses the chemo-resistant phenotype induced by
adipocyte secretory factors. These data imply that adipocyte-
secreted factors are crucial in modulating important tumor-
promoting molecules which, in turn, affect the outcome of
cancer therapy. Collectively, these results suggest that, under
obese state, melanoma cells in addition to acquiring a drug-
resistant phenotype also develop aggressive proliferative
phenotype, as compared to untreated counterparts.
Conclusions
This study provides a mechanistic link between obesity and
the outcome of chemotherapy in melanoma through in-
volvement of obesity-associated factors, which alter the sta-
tus of key signaling molecules involved in cell survival/
proliferation, drug efflux, and drug resistance. Interventions
leading to weight loss or prevention of weight gain restrict
melanoma growth (see the schematic overview in Fig. 5).
Malvi et al. Cancer & Metabolism  (2016) 4:21 Page 13 of 16
We investigated the impact of obesity in the outcome of
chemotherapy only in a mouse melanoma tumor isograft
model, so our findings justify further clinical and experi-
mental research.
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Additional file 1: Table S1. Composition of diets used in the study.
Normal diet (ND) was procured from Amrut Laboratory Animal Feed,
Pune, India, and high fat diet (HFD) was purchased from Provimi Animal
Nutrition Pvt. Ltd., Bangalore, India. *, HFD was also supplemented with
400 g groundnut and 200 g dried coconut per kg body weight of mice.
(PDF 169 kb)
Additional file 2: Table S2. Obesity-associated parameters in the
experimental ND mice recorded at the end of the experiment. ND male
C57BL/6J mice were divided into two major groups. One group was
orally treated with orlistat every alternate day before inoculating with
B16F10 cells. The second group was orally given vehicle control on every
alternate day for 8 weeks. Mice from both the groups (N = 11 per each
group) were injected (s.c.) with B16F10 cells (2 × 105 cells/mouse in
100 μl PBS). After tumor formation, vehicle or DTIC treatment was given
as per the experimental layout shown in Figure 1. Their body weight was
monitored weekly throughout the study, and serum was collected at the
end of the experiment. Blood glucose, serum TG, serum cholesterol,
serum-free fatty acids, and serum LDLc were measured. Serum factors
including leptin, adiponectin, insulin, resistin, IL-6, and TNF-α were
estimated by ELISA. The results are given as means ± standard deviation.
(PDF 113 kb)
Additional file 3: Figure S1. Effect of obesity-associated serum factors
on the protein level of P-gp, Cav-1, and FASN in B16F1 cells. B16F1 cells
were chronically grown in medium containing 5% serum collected from
ND or HFD C57BL/6J mice for 15 days. Thereafter, these cells were
subjected to immunofluorescence confocal staining of the indicated
molecules. The data were recorded using Zeiss LSM510 META Confocal
Microscope. (Scale bar = 20 μm). (PDF 189 kb)
Additional file 4: Figure S2. Effect of obesity-associated serum factors
on rhodamine-123 (Rh-123) efflux in B16F1 cells. B16F1 cells were
chronically grown in medium containing 5% serum collected from ND or
HFD C57BL/6J mice for 15 days. Thereafter, these cells were subjected
to Rh-123 efflux assay. Data were acquired on FACS Calibur and analyzed
using BD CellQuest Pro software. The data are representative of
experiments performed three times. (PDF 120 kb)
Additional file 5: Figure S3. Effect of inhibition of FASN, Cav-1, and
P-gp on response of B16F1 cells to DTIC. B16F1 cells were chronically
grown in medium containing 5% serum collected from experimental
ND or HFD C57BL/6J mice for 15 days. Thereafter, these cells were
subjected to long-term survival assay. First, cells were treated with
respective inhibitors followed by treatment of DTIC for 48 h. Then, the
medium was changed and fresh medium was added. The medium was
changed every 2–3 days. After 10 days, the cells were stained with 0.05%
crystal violet and images were taken using Olympus digital camera.
Data were quantitated using ImageJ software. The data are representative
of experiments performed three times; Ceru or C = cerulenin; MCD or M
=methyl β-cyclodextrin; Vera or V = verapamil. The results are given as
means ± standard deviation; *, p < 0.05. (PDF 666 kb)
Additional file 6: Figure S4. Effect of adipocyte-secreted factors on
the protein level of P-gp, Cav-1, and FASN in B16F1 cells. 3T3-L1 cells were
induced to differentiate with 500 μM 3-isobutyl-1-methylxanthine (IBMX) and
250 μM dexamethasone (DEX). The medium was changed every alternate













Fig. 5 Proposed model of impact of obesity and weight control interventions on the outcome of dacarbazine therapy in melanoma. Obesity-associated
factors impair the response of melanoma to DTIC by enhancing the levels of tumor-promoting molecules (solid red arrow marks). On the other hand,
controlling obesity through weight interventions causes normalization in obesity-associated factors. This in turn improves the efficacy of DTIC through
reducing in the levels of melanoma cell growth promoting molecules (dotted blue arrow marks)
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day. After 10 days, cells were washed twice with DMEM and fresh DMEM
without serum was added to the cells. After 18 h, conditioned medium (CM)
was collected from undifferentiated or differentiated 3T3-L1 cells. Thereafter,
B16F1 cells were cultured in these CM for 48 h, and these cells were subjected
to immunofluorescence confocal staining for the indicated molecules. The
data were recorded using Zeiss LSM510 META Confocal Microscope (Scale
bar = 20 μm); PA = preadipocytes; ID = differentiated 3T3-L1 cells induced to
differentiate by IBMX and DEX. (PDF 215 kb)
Additional file 7: Figure S5. Effect of adipocyte-secreted factors on
Rh-123 efflux in B16F1 cells. 3T3-L1 cells were induced to differentiate with
500 μM 3-isobutyl-1-methylxanthine (IBMX) and 250 μM dexamethasone
(DEX). The medium was changed every alternate day. After 10 days, cells
were washed twice with DMEM and fresh DMEM without serum was added
to the cells. After 18 h, conditioned medium (CM) was collected from
undifferentiated or differentiated 3T3-L1 cells. Thereafter, B16F10 or B16F1
cells were cultured in these CM for 48 h. Further, these cells were subjected
to Rh-123 efflux assay. Data were acquired on FACS Calibur and analyzed
using BD CellQuest Pro software. The data are representative of experiments
performed three times; PA = preadipocytes; ID = differentiated 3T3-L1 cells
induced by IBMX and DEX; Vera = verapamil. (PDF 150 kb)
Additional file 8: Figure S6. Effect of inhibiting FASN, Cav-1, and P-gp on
response of B16F1 cells to DTIC upon culture in CM collected from 3T3-L1 cells.
3T3-L1 cells were induced to differentiate with 500 μM 3-isobutyl-1-methylxan-
thine (IBMX) and 250 μM dexamethasone (DEX). The medium was
changed every alternate day. After 10 days, cells were washed twice with
DMEM and fresh DMEM without serum was added to the cells. After 18 h,
conditioned medium (CM) was collected from undifferentiated or differentiated
3T3-L1 cells. Thereafter, B16F10 or B16F1 cells were cultured in these CM for
48 h. First, cells were treated with respective inhibitors followed by treatment of
DTIC for 48 h. Then, the medium was changed and fresh medium was added.
The medium was changed every 2–3 days. After 10 days, the cells were stained
with 0.05% crystal violet and images were taken using Olympus digital camera.
Data were quantitated using ImageJ software. The data are representative
of experiments performed three times; PA = preadipocytes; ID = differentiated
3T3-L1 cells induced by IBMX and DEX; Ceru or C = cerulenin; MCD or M=
methyl β-cyclodextrin; Vera or V = verapamil. The results are given as means ±
standard deviation; *, p< 0.05. (PDF 538 kb)
Additional file 9: Figure S7. MS analysis on the distribution of DTIC in
tumors and organ samples collected from experimental ND or HFD
mice. Lysates of tumors and organ samples from the experimental ND
or HFD mice were prepared and subjected to liquid chromatography-
electrospray ionization tandem mass spectrometry (LC-ESI MS/MS).
The spectrum shows protonated mass of DTIC at 183.0984, m/z and
the product ions at m/z, 166.0733, 138.0396, and 123.0427 (similar
fragmentation patterns were observed in tumors and tissue samples of
mice treated with DTIC). The inset contains chemical structure of DTIC
with the fragmentation patterns marked. All the MS data were collected
in the presence of internal standards, where mass tolerance of DTIC
was maintained well within 3 ppm. (PDF 122 kb)
Abbreviations
Cav-1: Caveolin-1; DTIC: Dacarbazine; FASN: Fatty acid synthase; HFD: High
fat diet; ND: Normal diet; P-gp: P-glycoprotein
Acknowledgements
Authors thank Dr. S.C. Mande, Director, NCCS, Pune, India, and Dr. G.C. Mishra,
former Director, NCCS, Pune, India, for being very supportive and giving all the
encouragement to carry out this work. P.M. and S.V.S. thank University Grants
Commission (UGC), New Delhi, India; B.C., V.P., and N.M. thank the Council for
Scientific and Industrial Research (CSIR), India, for the research fellowship. The
support from Experimental Animal Facility (EAF), Confocal Microscopy Facility,
Fluorescence Activated Cell Sorter (FACS) Facility, Central Instrumental Facilities,
and technical staff of NCCS and other group members is also duly
acknowledged. The authors also acknowledge Amrita Agilent Analytical Research
Centre, Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam,
India, for the mass spectrometric data.
Funding
This work was supported in part by an intramural grant of National Centre for
Cell Science (NCCS), funded by the Department of Biotechnology (DBT),
Government of India, and an extramural grant from the Department of Science
and Technology (DST), Government of India (Grant No. SR/SO/HS-0136/2012).
The funding agencies had no involvement in the study design, data collection,
interpretation and analysis, decision to publish, or writing of the manuscript.
Availability of data and materials
All data generated or analyzed during this study are included in this article and
its Additional files 1, 2, 3, 4, 5, 6, 7, 8, and 9: Tables S1, S2 and Figures S1 to S7.
Authors’ contributions
MKB and PM conceived and designed the experiments. PM, BC, and MKB wrote
the manuscript; PM, BC, SVS, NM, VP, and MVV performed the experiments and
analyzed the data; RMR, MV, SSN, and BN performed the mass spectrometry-
related experiments; All the authors read, reviewed, and edited the manuscript.
Competing interests




All animal experiments were carried out as per the requirement and
guidelines of the Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA), Government of India, and after obtaining
permission of the Institutional Animal Ethics Committee (IAEC).
Note
This work was carried out for the partial fulfillment of a Ph.D. thesis (of P.M.)
submitted to Savitribai Phule Pune University, Pune, India. The work was
partly presented in the 33rd Annual Convention of Indian Association for
Cancer Research (IACR) in Kollam, Kerala, India, during February 13–15, 2014.
Author details
1Laboratory No. 6, National Centre for Cell Science (NCCS), Savitribai Phule
Pune University Campus, Ganeshkhind, Pune 411 007, India. 2Amrita School
of Biotechnology, Amrita Vishwa Vidyapeetham, Clappana P.O., Kollam 690
525, India. 3Present address: Laboratory of Neuroscience, Department of
Biotechnology and Bioinformatics, Hyderabad Central University, Hyderabad
500 046, India.
Received: 9 July 2016 Accepted: 23 November 2016
References
1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity,
and mortality from cancer in a prospectively studied cohort of U.S. adults. N
Engl J Med. 2003;348:1625.
2. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer
development in obesity. Nat Rev Cancer. 2011;11:886–95.
3. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new
mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15:484–98.
4. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al.
Global, regional, and national prevalence of overweight and obesity in
children and adults during 1980–2013: a systematic analysis for the Global
Burden of Disease Study 2013. Lancet. 2014;384:766–81.
5. Arnold M, Leitzmann M, Freisling H, Bray F, Romieu I, Renehan A, et al.
Obesity and cancer: an update of the global impact. Cancer Epidemiol.
2016;41:8–15.
6. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence
and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.
7. Font-Burgada J, Sun B, Karin M. Obesity and cancer: the oil that feeds the
flame. Cell Metab. 2016;23:48–62.
8. Griggs JJ, Sabel MS. Obesity and cancer treatment: weighing the evidence. J
Clin Oncol. 2008;26:4060–2.
9. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory
properties of adipose tissue macrophages recruited during diet-induced
obesity. Diabetes. 2007;56:16–23.
Malvi et al. Cancer & Metabolism  (2016) 4:21 Page 15 of 16
10. Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose
tissue on cancer development and progression. Endocr Rev. 2011;32:550–70.
11. Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Bustos M, Martínez
JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose
tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta.
1807;2011:664–78.
12. Mraz M, Haluzik M. The role of adipose tissue immune cells in obesity and
low-grade inflammation. J Endocrinol. 2014;222:R113–27.
13. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines:
role in cancer promotion. Horm Mol Biol Clin Investig. 2015;21:57–74.
14. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade
inflammation and insulin resistance in human obesity. Curr Pharm Des.
2008;14:1225–30.
15. Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K, et al.
Dietary factors and low-grade inflammation in relation to overweight and
obesity. Br J Nutr. 2011;106 Suppl 3:S5–S78.
16. Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA. Obesity, inflammation,
and cancer. Annu Rev Pathol. 2016;11:421–49.
17. Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C, et al.
Adipocyte–secreted factors synergistically promote mammary tumorigenesis
through induction of anti–apoptotic transcriptional programs and proto–
oncogene stabilization. Oncogene. 2003;22:6408–23.
18. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR,
et al. Adipocytes promote ovarian cancer metastasis and provide energy for
rapid tumor growth. Nat Med. 2011;17:1498–503.
19. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and
treatment of skin cancer. Am Fam Physician. 2000;62:357–68.
20. Cheymol G. Effects of obesity on pharmacokinetics implications for drug
therapy. Clin Pharmacokinet. 2000;39:215–31.
21. Wolin KY, Carson KG, Colditz A. Obesity and cancer. Oncologist. 2010;15:556–65.
22. Allott EH, Hursting SD. Obesity and cancer: mechanistic insights from
transdisciplinary studies. Endocr Relat Cancer. 2015;22:R365–86.
23. Chi M, Chen J, Ye Y, Tseng HY, Lai F, Tay KH, et al. Adipocytes contribute to
resistance of human melanoma cells to chemotherapy and targeted
therapy. Curr Med Chem. 2014;10:1255–67.
24. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy
for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer
Res. 2000;19:21–4.
25. Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese
patients with cancer. Nat Rev Clin Oncol. 2013;10:451–9.
26. Pandey V, Vijayakumar MV, Ajay AK, Malvi P, Bhat MK. Diet-induced obesity
increases melanoma progression: involvement of Cav-1 and FASN. Int J
Cancer. 2012;130:497–508.
27. Malvi P, Chaube B, Pandey V, Vijayakumar MV, Boreddy PR, Mohammad N, et al.
Obesity induced rapid melanoma progression is reversed by orlistat treatment
and dietary intervention: role of adipokines. Mol Oncol. 2015;9:689–703.
28. Sirin O, Kolonin MG. Treatment of obesity as a potential complementary
approach to cancer therapy. Drug Discov Today. 2013;18:567–73.
29. Lashinger LM, Rossi EL, Hursting SD. Obesity and resistance to cancer
chemotherapy: interacting roles of inflammation and metabolic
dysregulation. Clin Pharmacol Ther. 2014;96:458–63.
30. Ligibel JA, Alfano CM, Hershman D, Ballard RM, Bruinooge SS, Courneya KS,
et al. Recommendations for obesity clinical trials in cancer survivors: American
Society of Clinical Oncology Statement. J Clin Oncol. 2015;33:3961–7.
31. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Müller M,
et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID
mice. Nat Med. 1998;4:232–4.
32. Pandey V, Vijayakumar MV, Kaul-Ghanekar R, Mamgain H, Paknikar K, Bhat MK.
Atomic force microscopy, biochemical analysis of 3T3-L1 cells differentiated in
the absence and presence of insulin. Biochim Biophys Acta. 1790;2009:57–64.
33. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, et al.
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and
neoplastic transformation: a target for cancer chemotherapy. Leukemia.
2003;17:590–603.
34. Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, et al.
The multidrug transporter P-glycoprotein: a mediator of melanoma
invasion? J Invest Dermatol. 2008;128:957–71.
35. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the
management of obesity. Pharmacotherapy. 2000;20:270–9.
36. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of
fatty acid synthase with antitumor activity. Cancer Res. 2004;64:2070–5.
37. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, et al.
Chronic cisplatin treatment promotes enhanced damage repair and tumor
progression in a mouse model of lung cancer. Genes Dev. 2010;24:837–52.
38. Lev DC, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, et al. Exposure of
melanoma cells to dacarbazine results in enhanced tumor growth and
metastasis in vivo. J Clin Oncol. 2004;22:2092–100.
39. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes
transcriptional up-regulation of interleukin 8 and vascular endothelial
growth factor in melanoma cells: a possible escape mechanism from
chemotherapy. Mol Cancer Ther. 2003;2:753–63.
40. Hehlgans S, Cordes N. Caveolin-1: an essential modulator of cancer cell
radio-and chemoresistance. Am J Cancer Res. 2011;1:521–30.
41. Liu H, Wu X, Dong Z, Luo Z, Zhao Z, Xu Y, et al. Fatty acid synthase causes
drug resistance by inhibiting TNF-α and ceramide production. J Lipid Res.
2013;54:776–85.
42. Meena AS, Sharma A, Kumari R, Mohammad N, Singh SV, Bhat MK. Inherent
and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular
events involved. PLoS One. 2013;8:e61524.
43. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and
chemotherapeutic resistance. Drug Resist Updat. 2002;5:234–48.
44. Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor
progression. Cancer Metastasis Rev. 1994;13:223–33.
45. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein:
from genomics to mechanism. Oncogene. 2003;22:7468–85.
46. Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer
prevention: international evaluation of the evidence. Eur J Cancer Prev.
2002;2:S94–S100.
47. Chen J. Multiple signal pathways in obesity-associated cancer. Obes Rev.
2011;12:1063–70.
48. Sundaram S, Johnson AR, Makowski L. Obesity, metabolism and the
microenvironment: links to cancer. J Carcinog. 2013;12:19.
49. Schmidt S, Monk JM, Robinson LE, Mourtzakis M. The integrative role of
leptin, oestrogen and the insulin family in obesity-associated breast cancer:
potential effects of exercise. Obes Rev. 2015;16:473–87.
50. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine
factors in breast cancer risk and progression. Endocr Relat Cancer. 2007;14:
189–206.
51. Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on
mechanisms linking obesity to cancer risk and progression. Annu Rev Med.
2013;64:45–57.
52. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and
adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta.
1831;2013:1533–41.
53. Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS,
et al. Adipocytes impair leukemia treatment in mice. Cancer Res. 2009;69:
7867–74.
54. Bochet L, Meulle A, Imbert S, Salles B, Valet P, Muller C. Cancer-associated
adipocytes promote breast tumor radioresistance. Biochem Biophys Res
Commun. 2011;411:102–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Malvi et al. Cancer & Metabolism  (2016) 4:21 Page 16 of 16
